SpaceOAR System is an absorbable hydrogel spacer that is injected into the perirectal space between the prostate and rectum before radiotherapy for prostate cancer. After developing the final scope we determined that this topic was no longer suitable for medical technologies guidance. The topic will now be considered for selection by the technology appraisals programme.
Status In progress
Decision Selected
Process MTG
ID number 451

Project Team

Project lead TBC

Email enquiries


External assessment group Newcastle Upon Tyne Hospitals
Manufacturers Boston Scientific (Formerly Augmenix)
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
Professional groups British Uro-Oncology Group
  Royal College of Radiologists
  Prostate Scotland
  The Society and College of Radiographers


Key events during the development of the guidance:

Date Update
20 May 2019 Scope published
25 March 2019 Stakeholder registration opens

For further information on our processes and methods, please see our CHTE processes and methods manual